These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34775915)

  • 1. A Two-Stage Decision Making Approach for Safety Studies.
    Kim J; Huang Z
    J Biopharm Stat; 2021 Nov; 31(6):828-837. PubMed ID: 34775915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance, Errors, Power, and Sample Size: The Blocking and Tackling of Statistics.
    Mascha EJ; Vetter TR
    Anesth Analg; 2018 Feb; 126(2):691-698. PubMed ID: 29346210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian sequential design using alpha spending function to control type I error.
    Zhu H; Yu Q
    Stat Methods Med Res; 2017 Oct; 26(5):2184-2196. PubMed ID: 26187736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size re-estimation in clinical trials.
    Wang P; Chow SC
    Stat Med; 2021 Nov; 40(27):6133-6149. PubMed ID: 34433225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Composite sequential Monte Carlo test for post-market vaccine safety surveillance.
    Silva IR
    Stat Med; 2016 Apr; 35(9):1441-53. PubMed ID: 26561330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Go/No-Go Decision-Making Properties Between Single Arm Phase II Trial Designs in Oncology.
    Broglio K; Marshall J; Yu B; Frewer P
    Ther Innov Regul Sci; 2022 Mar; 56(2):291-300. PubMed ID: 34988927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of five approaches to decision-making for a first clinical trial of efficacy.
    Kirby S; Chuang-Stein C
    Pharm Stat; 2017 Jan; 16(1):37-44. PubMed ID: 27678332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry.
    Yoshida M; Matsuyama Y
    J Biopharm Stat; 2016; 26(5):842-58. PubMed ID: 26391147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints.
    Uozumi R; Hamada C
    J Biopharm Stat; 2017; 27(1):84-100. PubMed ID: 26881477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new futility test approach in clinical interim data monitoring.
    Xue D
    Pharm Stat; 2012; 11(6):468-75. PubMed ID: 23015479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.
    Pritchett Y; Jemiai Y; Chang Y; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata-Andía JB; Thompson T; Appelbaum E; Audhya P; Andress D; Zhang W; Solomon S; Manning WJ; Thadhani R
    Clin Trials; 2011 Apr; 8(2):165-74. PubMed ID: 21478328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of phase 2 interim analysis to expedite drug development decisions.
    Huang J; Das A; Burger HU; Zhong W; Zhang W; Lieberman G
    Contemp Clin Trials; 2014 Jul; 38(2):235-44. PubMed ID: 24854415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exact critical values for group sequential designs with small sample sizes.
    Rom DM; McTague JA
    J Biopharm Stat; 2020 Jul; 30(4):752-764. PubMed ID: 32151177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.